GPX4 and central nervous system cancer: These findings uncover a TP53 mutation-β-catenin-ΔNp63-GPX4 axis that drives ferroptosis resistance and glioma malignancy, highlighting ΔNp63 as a potential therapeutic target in TP53-mutant GBM.